Aqemia Raises $38M to Advance AI-Driven Drug Discovery
Aqemia combines deep-tech and biotechnology to tackle challenging diseases.
Company Name: Aqemia
Location: Paris, France
Industry: TechBio (AI-Powered Drug Discovery)
Funding Details:
Amount: $38M (Total Funding: $100M)
Investors: Cathay Innovation (Lead), Wendel, Bpifrance Large Venture, Eurazeo, Elaia
Purpose of Investment:
The funds will accelerate Aqemia’s development, focusing on clinical trial preparations and global expansion initiatives.
Leadership:
CEO: Maximilien Levesque
Product:
Aqemia’s proprietary platform merges atomic-scale physics with generative AI to design novel medicines for critical diseases. Its technology has driven multiple successful drug discovery programs, progressing toward in vivo optimization.
About the Company:
Founded to transform drug discovery, Aqemia combines deep-tech and biotechnology to tackle challenging diseases. The company collaborates with pharmaceutical giants and advances its internal drug pipelines using a cutting-edge AI-powered molecular modeling approach.
Marking its next growth phase, Aqemia plans to open a new office in London’s King’s Cross area in January 2025, tapping into the UK’s robust life sciences and techbio ecosystem. The expansion supports its global recruitment strategy, with roles available across multiple levels as the company scales its scientific and operational capabilities.
